Carcinoid tumors (CT) are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs.
In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumour, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhoea, malabsorption, and breathing difficulties, etc.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/carcinoid-tumor-market
The Carcinoid Tumor market report also covers emerging drugs, current treatment practices, Carcinoid Tumor market share of the individual therapies, current and forecasted Carcinoid Tumor Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Carcinoid Tumor treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Carcinoid Tumor Market Key Facts
As per the study conducted by Siddiqui et al. titled “The Epidemiology of Carcinoid Tumors of Small and Large Intestine in the USA: A National Inpatient Sample Analysis” the malignant CTs of small intestine were the most common out of all CTs of the intestine. Interestingly there was male predominance in CTs of the small intestine and female predominance in CTs of the large intestine.
The National Organization for Rare Disorders estimates that 27 new cases of Carcinoid Tumour per million are diagnosed in the United States per year out of which, only about 10% develops carcinoid syndrome.
According to the study titled “Carcinoid syndrome” conducted by Rehman et al., in Japan, the rate of incidence of carcinoid tumors was 5.25 cases per 100,000 in 2004.
Key Benefits of Carcinoid Tumor Market Report
-
Carcinoid Tumor market report provides an in-depth analysis of Carcinoid Tumor Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Carcinoid Tumor market report will help in developing business strategies by understanding the Carcinoid Tumor Market trends & developments, key players and future market competition that will shape and drive the Carcinoid Tumor market in the upcoming years.
-
The Carcinoid Tumor market report covers Carcinoid Tumor current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Carcinoid Tumor market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Carcinoid Tumor Market
The Carcinoid Tumor market size is expected to increase during the forecast period owing to the rise in awareness and incidence of the disease in the 7MM.
The Carcinoid Tumor market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Carcinoid Tumor market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Carcinoid Tumor market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Carcinoid Tumor Epidemiology
The Carcinoid Tumor epidemiology section covers insights about historical and current Carcinoid Tumor patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Carcinoid Tumor Drugs Uptake and Key Market Players
The Carcinoid Tumor Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Carcinoid Tumor market or expected to get launched in the market during the study period. The analysis covers Carcinoid Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Carcinoid Tumors (CT) market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and expected the launch of emerging therapies during the forecast period.
The key companies in the Carcinoid Tumor market include:
Bristol-Myers Squibb
Merck Sharp & Dohme
Exelixis
And others.
Some of the Carcinoid Tumor Therapies covered in the report include:
Lutathera
Pembrolizumab
Nivolumab
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Carcinoid Tumor Competitive Intelligence Analysis
4. Carcinoid Tumor Market Overview at a Glance
5. Carcinoid Tumor Disease Background and Overview
6. Carcinoid Tumor Patient Journey
7. Carcinoid Tumor Epidemiology and Patient Population
8. Carcinoid Tumor Treatment Algorithm, Current Treatment, and Medical Practices
9. Carcinoid Tumor Unmet Needs
10. Key Endpoints of Carcinoid Tumor Treatment
11. Carcinoid Tumor Marketed Products
12. Carcinoid Tumor Emerging Therapies
13. Carcinoid Tumor Seven Major Market Analysis
14. Attribute Analysis
15. Carcinoid Tumor Market Outlook (7 major markets)
16. Carcinoid Tumor Access and Reimbursement Overview
17. KOL Views on the Carcinoid Tumor Market.
18. Carcinoid Tumor Market Drivers
19. Carcinoid Tumor Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Carcinoid Tumor Epidemiology Forecast
DelveInsight's Carcinoid Tumor Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Carcinoid Tumours in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Carcinoid Tumor Pipeline Insights
Carcinoid Tumor Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Carcinoid Tumor market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
